GL1X · GenesisL1 explorer

MolNFT v1 · #86435 · protein

Discovery of oral polo-like kinase (plk) inhibitors with enhanced selectivity profile using residue targeted drug design

4B6L · SERINE/THREONINE-protein kinase PLK3: “Discovery of oral polo-like kinase (plk) inhibitors with enhanced selectivity profile using residue targeted…”. X-ray diffraction, 2 ligands (9ZP, SO4), 2 pockets (best druggability 0.66).…

PDB
4B6L
Type
protein
Length
281 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
SERINE/THREONINE-protein kinase PLK3
EC
2.7.11.21
UniProt
Q9H4B4
Ligands
9ZP, SO4
Pockets
2 · best druggability 0.66

Structure

x-ray diffraction · 1 distinct chain · 37% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASERINE/THREONINE-protein kinase PLK3 (EC 2.7.11.21)protein28137% helix, 17% strandQ9H4B4

Ligands and binding sites

  • 9ZP · 4-[[(4R)-5-cyclopentyl-4-ethyl-3a,4-dihydro-3H-[1,2,4]triazolo[4,3-f]pteridin-7-yl]amino]-N-cyclopropyl-3-methoxy-benzamide · ligand · chains A
  • SO4 · Sulfate ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13840.660.79509ZP
21230.420.7618empty

Compared structures

  • 4B6L · Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9H4B4 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase PLK3 (Q9H4B4) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.